Hikma Pharmaceuticals PLC - Asset Resilience Ratio
Hikma Pharmaceuticals PLC (HIK) has an Asset Resilience Ratio of 0.49% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Hikma Pharmaceuticals PLC PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Hikma Pharmaceuticals PLC's Asset Resilience Ratio has changed over time. See Hikma Pharmaceuticals PLC net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hikma Pharmaceuticals PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hikma Pharmaceuticals PLC stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX25.00 Million | 0.49% |
| Total Liquid Assets | GBX25.00 Million | 0.49% |
Asset Resilience Insights
- Limited Liquidity: Hikma Pharmaceuticals PLC maintains only 0.49% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hikma Pharmaceuticals PLC Industry Peers by Asset Resilience Ratio
Compare Hikma Pharmaceuticals PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Hikma Pharmaceuticals PLC (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Hikma Pharmaceuticals PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.49% | GBX25.00 Million ≈ $3.04K |
GBX5.13 Billion ≈ $624.54K |
-0.03pp |
| 2023-12-31 | 0.51% | GBX24.00 Million ≈ $2.92K |
GBX4.68 Billion ≈ $569.42K |
+0.02pp |
| 2022-12-31 | 0.49% | GBX22.00 Million ≈ $2.68K |
GBX4.47 Billion ≈ $543.99K |
-0.06pp |
| 2021-12-31 | 0.55% | GBX24.00 Million ≈ $2.92K |
GBX4.37 Billion ≈ $531.95K |
-0.03pp |
| 2020-12-31 | 0.58% | GBX24.00 Million ≈ $2.92K |
GBX4.13 Billion ≈ $503.11K |
0.00pp |
| 2019-12-31 | 0.59% | GBX23.00 Million ≈ $2.80K |
GBX3.93 Billion ≈ $478.17K |
-0.02pp |
| 2018-12-31 | 0.60% | GBX21.00 Million ≈ $2.56K |
GBX3.50 Billion ≈ $425.48K |
-0.05pp |
| 2017-12-31 | 0.65% | GBX22.00 Million ≈ $2.68K |
GBX3.39 Billion ≈ $412.22K |
+0.19pp |
| 2016-12-31 | 0.46% | GBX20.00 Million ≈ $2.43K |
GBX4.36 Billion ≈ $530.85K |
-0.31pp |
| 2015-12-31 | 0.77% | GBX20.00 Million ≈ $2.43K |
GBX2.60 Billion ≈ $315.98K |
+0.41pp |
| 2014-12-31 | 0.36% | GBX8.00 Million ≈ $973.37 |
GBX2.25 Billion ≈ $273.88K |
-0.01pp |
| 2013-12-31 | 0.36% | GBX7.00 Million ≈ $851.70 |
GBX1.93 Billion ≈ $234.70K |
-0.28pp |
| 2012-12-31 | 0.64% | GBX11.04 Million ≈ $1.34K |
GBX1.73 Billion ≈ $210.50K |
+0.47pp |
| 2011-12-31 | 0.16% | GBX2.60 Million ≈ $315.74 |
GBX1.58 Billion ≈ $191.71K |
-0.16pp |
| 2010-12-31 | 0.32% | GBX3.57 Million ≈ $434.73 |
GBX1.12 Billion ≈ $135.76K |
+0.09pp |
| 2009-12-31 | 0.23% | GBX2.33 Million ≈ $283.98 |
GBX1.02 Billion ≈ $124.44K |
+0.14pp |
| 2008-12-31 | 0.08% | GBX819.00K ≈ $99.65 |
GBX966.46 Million ≈ $117.59K |
-0.54pp |
| 2007-12-31 | 0.63% | GBX5.63 Million ≈ $684.76 |
GBX894.04 Million ≈ $108.78K |
-0.46pp |
| 2006-12-31 | 1.09% | GBX5.34 Million ≈ $649.36 |
GBX488.36 Million ≈ $59.42K |
-0.19pp |
| 2005-12-31 | 1.29% | GBX5.12 Million ≈ $622.96 |
GBX397.96 Million ≈ $48.42K |
-1.83pp |
| 2004-12-31 | 3.12% | GBX7.69 Million ≈ $935.89 |
GBX246.48 Million ≈ $29.99K |
-- |
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and spe… Read more